• By Ginger Plumbo

Mayo Clinic Physicians Present New Research on Heart Transplant Care and Long-term Outcomes

April 20, 2015

ROCHESTER, Minn. — Heart transplant experts from Mayo Clinic presented findings from three recent clinical studies involving heart transplant patients. The presentations took place during the 2015 International Society of Heart & Lung Transplant (ISHLT) in Nice, France, April 15–18.

Two hands holding a heartMayo Clinic physicians presented oral and poster presentations on 16 studies at ISHLT this year. The conference attracts 3,000 health care professionals from 45 countries who represent more than 15 different medical disciplines involved in the management and treatment of end-stage heart and lung disease. A few highlights of the Mayo Clinic-related research include:

“Are psychosocial characteristics predictive of death and rehospitalization after destination left ventricular assist device?”

  • This study examined psychosocial factors, such as drug use, depression and nonsmoking status to determine if they are associated with higher rehospitalization risk after a patient has received a left ventricular assist device (LVAD).
  • The study concluded that drug use, depression and nonsmoking status are associated with higher rehospitalization risk after LVAD. These data may be helpful in stratifying and communicating risk to patients who are considering LVAD as destination therapy.
  • Mayo Clinic researchers involved in this study include Shannon Dunlay, M.D., M.S.; Sarah Schettle, PAC; David Snipelisky, M.D.; Shashank Sharma; Sudhir Kushwaha, M.D.; John Stulak, M.D.
  • Date of presentation: April 15

“Sirolimus-based immunosuppression results in lower incidence of post-transplantation lymphoproliferative disorders in heart transplant recipients”

  • This study examines whether the use of sirolimus-based immunosuppression (SRL) drug therapy affects whether a patient will be diagnosed with a form of cancer that affects transplant patients. Known as post-transplantation lymphoproliferative disorder, this type of malignancy occurs in 2 percent to 9 percent of heart transplant patients.
  • The study concluded that these initial observations suggest that post-transplantation lymphoproliferative disorders PTLD incidence is lower in heart transplant recipients on sirolimus-based immunosuppression. The mechanism may be due to the powerful anti-proliferative effect of sirolimus. This study highlights another potential advantage of SRL that may improve long-term survival following heart transplantation.
  • Mayo Clinic researchers involved in this study include Darko Vucicevic, M.D.; Richard Daly, M.D.; Eric Steidley, M.D.; Robert Scott, M.D.; Walter Kremers, Ph.D.; Brooks Edwards, M.D.; Sudhir Kushwaha, M.D.
  • Date of presentation: April 17

“HVAD insertion via right ventricular interposition: a novel strategy for biventricular support”

  • This presentation will feature the case of a Mayo patient who received a new implantable ventricular support device that was designed for smaller patients whose chest cavities will not accommodate existing ventricular support devices. With the Hybrid Ventricular Assist Device (HVAD), Mayo physicians were able to support the patient while she awaited heart transplant.
  • Mayo Clinic physicians involved in this case include David Joyce, M.D.; John Stulak, M.D.; Sudhir Kushwaha, M.D.; Richard Daly, M.D.; Lyle Joyce, M.D., Ph.D.
  • Date of presentation: April 17

The ISHLT was created in 1981 by a small group of cardiologists and cardiac surgeons who were dedicated to improving the care of patients with advanced heart or lung disease.

About Transplantation at Mayo Clinic
Mayo Clinic has one of the nation’s largest and most experienced transplant practices, with campuses in Minnesota, Arizona and Florida. Over 200 doctors in transplant medicine and surgery perform about 1,800 transplants a year, and have a long track record of excellent outcomes. The heart transplant program at Mayo Clinic in Rochester is part of the integrated William J. von Liebig Transplant Center, where more than 800 solid organ and blood and marrow transplants take place every year. The opportunity to collaborate with multiple transplant programs allows Mayo Clinic patients access to a multidisciplinary transplant team and the opportunity for multiorgan transplantation if necessary.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or https://newsnetwork.mayoclinic.org/.

MEDIA CONTACT: Ginger Plumbo, Mayo Clinic Public Affairs, 507-284-5005, Email: newsbureau@mayo.edu

Is this for cost reasons, overloading-the-system reasons, a combination, or something else? – Does it help any to use the non-toll-free access number? It would be great also if Mayo would adopt the mobile version of Skype. I believe we can only use the desktop version. Might save some money, maybe. Maybe.

COMMENT

Just curious if this is the extent of the communication that took place? Were admin assistants sent a separate message about this? I have scheduled 2 meetings for next week requiring a global crossing and A)did not see this article till just now (2:20 Monday 10/30) and B) received no pushback from my super fantastic admin assistant.

COMMENT

Just for clarification, what is the scope of the effected sites? Does this apply to the Health System or the whole upper Midwest or to all Mayo Clinic locations?

COMMENT

One other idea: as everyone who has Level3 also has a Webex account, just use Webex to host your meetings and the Audio on your computer, then there is no Phone system involved (does require a computer headset/audio though).

COMMENT
@gereonb

One other idea: as everyone who has Level3 also has a Webex account, just use Webex to host your meetings and the Audio on your computer, then there is no Phone system involved (does require a computer headset/audio though).

Jump to this post

Somehow I was mistaken, It was Skype that had built-in audio. our Leve3 Webex does have that feature but it is disabled by default, maybe they could look into enabling it.

COMMENT
@jillhill

Just curious if this is the extent of the communication that took place? Were admin assistants sent a separate message about this? I have scheduled 2 meetings for next week requiring a global crossing and A)did not see this article till just now (2:20 Monday 10/30) and B) received no pushback from my super fantastic admin assistant.

Jump to this post

Thank You for the question. We went the route of a “This Week at Mayo Clinic" article as it’s available and viewable by the most people involved in scheduling and/or participating in meetings. We are not expecting all Level 3 meetings to be cancelled/re-scheduled but wherever possible it may relieve resources during the Epic go-live.

** Comment posted by subject matter expert **

COMMENT
@mariastahl1

Is this for cost reasons, overloading-the-system reasons, a combination, or something else? – Does it help any to use the non-toll-free access number? It would be great also if Mayo would adopt the mobile version of Skype. I believe we can only use the desktop version. Might save some money, maybe. Maybe.

Jump to this post

Thank You for your question. The primary reason for this recommendation is due to the concern of overloading the voice circuits between Mayo Clinic and the service providers. Utilizing those circuits for a very large volume of lengthy Level 3 calls can cause incoming calls from our patients to be blocked or outgoing calls to our patients to be blocked. There is also a charge for every person calling in to a Level 3 meeting. Other conferencing methods continue to be pursued and utilized when and where feasible.

** Comment posted by subject matter expert **

COMMENT
@bterrill

Just for clarification, what is the scope of the effected sites? Does this apply to the Health System or the whole upper Midwest or to all Mayo Clinic locations?

Jump to this post

The primary concern is around Level 3 call volumes in MCHS MN and Rochester. However, since participants and/or the Chairperson in a Level 3 meeting could be from any site, the recommendation is to limit nonessential use of Level 3 meetings across the enterprise during the EPIC go-live time frame.

** Comment posted by subject matter expert **

COMMENT
Please login or register to post a reply.